Exchange: NASDAQ·Updated 04:10 PM EST
CLLS logo

CLLS Cellectis

$1.03
$0.03
(2.83%)
Today
Closed $1.03
$0.00
(0.00%)
After Hours
Reported EarningsNov 13
Mkt Cap$76.67M
Vol6,020.00

About CLLS

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
79

Extremely Bullish Sentiment

How do you feel about CLLS?

PennyScam
$CLLS Let’s see what these three conferences can pull off for us.👍🏻🙏 We should see some action in late November early December. At this stage I don’t see much happening. No one has to pull the trigger on either side. All CEOs are just flopping around doing nothing. Ck
2
BiotechButterflies
$CLLS ... nice data drop - and now the race into the clinic... VERVE have shown how attractive this was for Lilly to pay big dollars to own...
1
kshonstocks
$CLLS Cellectis S.A. (NASDAQ: CLLS) has $2.29 in total cash per share based on the most recent quarter (MRQ) data per AI
1
StocktwitsEarnings
$CLLS Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.61 down -3150.00% YoY • Reported revenue of $5.44M down -85.36% YoY • Cellectis believes its cash and cash equivalents of $28.2M and deposits of $118.3M, following full implementation of realignment as planned, will fund operations into the second half of 2028.

Advertisement|Remove ads.